FILTER
LATEST INTERVIEWS
Peter C. Dougherty
PRESIDENT & CEO, ARGONAUT GOLD
Argonaut Gold updates on progress at its gold projects throughout North America.
Stephen Smithyman
CEO, KANU EQUIPMENT
Kanu Equipment comments on the challenges and opportunities in Africa for a mining and construction dealership.
Marco Salcedo
DIRECTOR, AMVAC MÉXICO
AMVAC Mexico explains how it is growing through developing its portfolio with a particular emphasis on biological products.
Luke Alexander
PRESIDENT, CEO AND DIRECTOR, NEWCORE GOLD LTD.
Newcore Gold enthuses about the prospects of its major drilling campaign at its Enchi gold project in Ghana.
Dr. Paul Kau
EHS TECHNICAL DIRECTOR FOR ASIA, GOLDER ASSOCIATES, SINGAPORE
Golder Associates in Singapore comment on the longer term implications of the pandemic on businesses and how environmental, health and safety concerns have come to the fore.
Miguel Caillaux, Jonathan Campbell, Luz Blancas
GENERAL MANAGER & DIRECTOR / DEPUTY GENERAL MANAGER / COMMERCIAL MANAGER, CERTIMIN S.A.
Certimin describes how it continued to expand its business and its partnerships in Peru throughout 2020.
Jody Kuzenko
PRESIDENT & CEO, TOREX GOLD RESOURCES
Torex Gold explains why 2020 was an exceptionally good year at El Limón Guajes.
Liam Morrissey
CEO, MS RISK
MS Risk speaks of the danger that the war in the Sahel represents to mines and businesses.
Alfredo Ison
EXECUTIVE PRESIDENT, QUÍMICA DELTA
Química Delta explains how Mexico’s chemical distribution market has fared throughout the current difficult period.
Simon Meadows Smith
MANAGING DIRECTOR, SEMS EXPLORATION SERVICES
SEMS Exploration is a consultancy and exploration services company in West Africa. Geologist and Managing Director, Simon Meadows Smith, walks us through the trends he observes in the region.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
